Skip to main content
. 2020 Sep 20;21(18):6898. doi: 10.3390/ijms21186898

Figure 1.

Figure 1

Representative Hsp90 C-terminal domain inhibitors. First Hsp90 C-terminal domain (CTD) inhibitor 1 (IC50 ~700 μM SKBr3 cancer cells) [17,21], synthetic novobiocin derivatives 2 and 3 (IC50 < 1 μM SKBr3 cancer cells) [22,23] and deguelin (4), a flavin natural product.